Pharmaceutical compositions comprising cholesteryl-alpha-glucosyltransferase for the treatment of Helicobacteri pylori infections

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes pharmaceutical compositions and methods involving inhibitors of cholesteryl-alpha-glucosyltransferase, an enzyme from Helicobacter pylori. By inhibiting this enzyme, the invention aims to prevent or treat Helicobacter pylori infections and associated diseases, such as gastritis, peptic ulcers, and gastric cancer. The patent also covers screening methods to identify new inhibitors and the potential use of enzyme-based vaccines.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of new drugs to treat acute or chronic Helicobacter pylori infections by targeting cholesteryl-alpha-glucosyltransferase.
• Therapeutic regimens for peptic ulcers, chronic gastritis, or MALT lymphoma linked to H. pylori.
• Combining cholesteryl-alpha-glucosyltransferase inhibitors with standard antibiotics for improved therapy.
• Creation of vaccines containing cholesteryl-alpha-glucosyltransferase or its gene for immunization against H. pylori.
• Development of diagnostic kits to identify drugs that inhibit the enzyme through screening assays.
• Utilization of cholesterol-rich diets as adjunct therapies to enhance immune response and reduce bacterial colonization.

BenefitsContent extracted from patent full text and abstract with AI.

• Targets a specific and essential bacterial enzyme critical for H. pylori's immune evasion, potentially increasing treatment success and reducing recurrence.
• May overcome limitations of current antibiotic therapies, such as resistance and incomplete eradication.
• Allows for development of both drug-based and vaccine-based solutions, providing flexibility in preventive and therapeutic strategies.
• Potentially fewer side effects by selectively inhibiting the bacterial enzyme instead of broad-spectrum approaches.
• Facilitates personalized and combination therapies with existing treatments for more robust clinical outcomes.
• The included screening methods accelerate the discovery of novel therapeutic agents.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention refers to pharmaceutical compositions comprising cholesteryl-±-glucosyltransferase from Helicobacter, inhibitors of cholesteryl-±-glucosyltransferase and the use thereof for the manufacture of a medicament for the prevention or/and treatment of Helicobacter infection or/and a Helicobacter -associated disease. Another subject is the screening method for novel inhibitors of cholesteryl-±-glucosyltransferase.